Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, Henk M., Plesner, Torben, Laubach, Jacob P., Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C., Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J., Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M., Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G.·2015·New England Journal of Medicine
DOI 10.1056/nejmoa1506348

Cited by (1,000)

Items 501–600 of 1,000

  1. Therapeutics to harness the immune microenvironment in multiple myeloma
    James John Ignatz-Hoover, James Joseph Driscoll · 2022 · Cancer Drug Resistance
  2. Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59
    Kieran Brennan, Katrine Fladeland Iversen, Alfonso Blanco, Thomas Lund, Torben Plesner, Margaret M. Mc Gee · 2022 · Cells
  3. Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
    Lijie Xing, Yuntong Liu, Jiye Liu · 2023 · Cancers
  4. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
    Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Panagiotis Malandrakis, Evgenia Verrou, Stavros Golfinopoulos, Magdalini Migkou, Kyriaki Manousou et al. · 2024 · American Journal of Hematology
  5. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis
    Florent Malard, Jean‐Luc Harousseau, Mohamad Mohty · 2016 · Cancer Treatment Reviews
  6. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma
    Rebecca Karp Leaf, Dina Stroopinsky, Athalia Rachel Pyzer, Ada M. Kruisbeek, Sandra van Wetering, Abigail J. Washington, Adam Ephraim, Leandra Cole, Adam Morin, Salvia Sanjay Jain et al. · 2017 · Journal of Immunotherapy
  7. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
    Emily Hoylman, Anna Bess Brown, Anthony J. Perissinotti, Bernard Lawrence Marini, Matthew James Pianko, Jing Christine Ye, Erica Leigh Campagnaro, Victoria R. Nachar · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
  8. Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
    Man Luo, Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Ajai Chari, Jesús F. San Miguel, Cyrille Touzeau, Kenshi Suzuki, Martin Kaiser, Robin L. Carson et al. · 2020 · The Journal of Clinical Pharmacology
  9. CD38 contributes to human natural killer cell responses through a role in immune synapse formation
    Mathieu Le Gars, Christof Seiler, Alexander W. Kay, Nicholas L. Bayless, Elsa Sola, Elina Starosvetsky, Lindsay Moore, Shai S. Shen-Orr, Natali Aziz, Purvesh Khatri et al. · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  10. Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management
    Young Gi Min, Andrea Visentin, Chiara Briani, Yusuf A. Rajabally · 2024 · Journal of Neurology Neurosurgery & Psychiatry
  11. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
    Michael M. Boyiadzis, Michael Bishop, Rafat Abonour, Kenneth Carl Anderson, Stephen Maxted Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen van Besien, Peter Leif Bergsagel et al. · 2016 · Journal for ImmunoTherapy of Cancer
  12. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study)
    Anna Kalff, Tiffany T. Khong, Sridurga Mithraprabhu, Krystal Bergin, John Reynolds, Kathryn M. Bowen, Anjan Thakurta, Roberto Z. Guzman, Maria Wang, Suzana S. Couto et al. · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
  13. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR
    Xiaohui Zeng, Liubao Peng, Peng Ye, Chongqing Tan, Xiaomin Wan · 2020 · Clinical Therapeutics
  14. Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
    Natalie Baum, Ralf Fliegert, Andreas Bauche, Julia Hambach, Stephan Menzel, Friedrich Haag, Peter Bannas, Friedrich Koch‐Nolte · 2020 · Cancers
  15. Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukemia
    Shujing Yue, Jingnan An, Yifan Zhang, Jiaying Li, Cenzhu Zhao, Jingyi Liu, Lanlan Liang, Huanli Sun, Yang Xu, Zhiyuan Zhong · 2023 · Advanced Materials
  16. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides
    Yun‐Tsan Chang, Pacôme Prompsy, Susanne Kimeswenger, Yi-Chien Tsai, Desislava Ignatova, Olesya Pavlova, Christoph Iselin, Lars Einar French, Mitchell P. Levesque, François Kuonen et al. · 2024 · Nature Communications
  17. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
    Bernard D. Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy · 2016 · Transplantation and Cellular Therapy
  18. Key Molecular Drivers of Chronic Lymphocytic Leukemia
    Suliman Abdallah Alsagaby, Paul Brennan, Chris J. Pepper · 2016 · Clinical Lymphoma Myeloma & Leukemia
  19. How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma
    Craig C. Hofmeister, Sagar Lonial · 2016 · Journal of Clinical Oncology
  20. Advances in immunotherapy in multiple myeloma
    Leora S. Boussi, Rubén Niesvizky · 2017 · Current Opinion in Oncology
  21. Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
    Klemens Ablasser, Nicolas Verheyen, Theresa Glantschnig, Giulio Agnetti, Peter P. Rainer · 2018 · Current Medicinal Chemistry
  22. Daratumumab: Therapeutic asset, biological trap!
    Véronique Deneys, Claire Thiry, Alex Frelik, Cécile Debry, B. Martin, Chantal Doyen · 2018 · Transfusion Clinique et Biologique
  23. 1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression
    Duurenjargal Tseeleesuren, Rajni Kant, Chia‐Hung Yen, Hui‐Hua Hsiao, Yi‐Ming Arthur Chen · 2018 · Frontiers in Pharmacology
  24. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma
    Saad Z. Usmani, Imran Khan, Christopher W. Chiu, David Foureau, Lawrence J. Druhan, Katherine Rigby, Tineke Casneuf, Amy Kate Sasser · 2018 · Experimental Hematology and Oncology
  25. The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
    Lucas Resende Salgado, Shutao Wang, Ava Adler, Sanders Chang, Meng Ru, Erin L Moshier, Kavita Vyas Dharmarajan, Hearn Jay Cho, Richard Lorne Bakst · 2018 · Advances in Radiation Oncology
  26. The Role of Long-Lived Plasma Cells in Antibody-Mediated Rejection of Kidney Transplantation: An Update
    Hua Su, Chunyun Zhang, Jihong Lin, Hans‐Peter Hammes, Chun Zhang · 2019 · Kidney Diseases
  27. BID and the α-bisabolol-triggered cell death program: converging on mitochondria and lysosomes
    Antonella Rigo, Isacco Ferrarini, Erika Lorenzetto, Elena Darra, Irene Liparulo, Christian Bergamini, Cinzia Sissa, Elisabetta Cavalieri, Fabrizio Vinante · 2019 · Cell Death and Disease
  28. Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma
    Yael Chava Cohen, Albert Oriol, Ka Lung Wu, Noa Lavi, Philip Vlummens, Carolyn Chang Jackson, Wendy Garvin, Robin L. Carson, Wendy A. Crist, Jiayu Fu et al. · 2020 · Clinical Lymphoma Myeloma & Leukemia
  29. Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia
    Valentin V. Barsan, Sneha Ramakrishna, Kara Lynn Davis · 2020 · Current Oncology Reports
  30. A new era of immune therapy in multiple myeloma
    Yu‐Tzu Tai, Kenneth Carl Anderson · 2016 · Blood
  31. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma
    Samer Al Hadidi, Courtney Nicole Miller-Chism, Rammurti T. Kamble, Martha Pritchett Mims · 2020 · Clinical Lymphoma Myeloma & Leukemia
  32. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice
    Issam S. Hamadeh, Donald C. Moore, Allison L. Martin, Allison Karabinos, Hailey Hill, Ami P Ndiaye, Jordan Robinson, Barry A. Paul, Shebli Atrash, Manisha Bhutani et al. · 2021 · Clinical Lymphoma Myeloma & Leukemia
  33. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma
    Chantal Reina-Ortiz, David Giraldos, Gemma Azaceta, Luis Palomera, Isabel Marzo, Javier Naval, Martín Villalba, Alberto Anel · 2022 · Cells
  34. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
    Ja Min Byun, Chang‐Ki Min, Kihyun Kım, Soo‐Mee Bang, Je‐Jung Lee, Jin Seok Kim, Sung‐Soo Yoon, Youngil Koh · 2022 · Journal of Hematology & Oncology
  35. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non- MMSET Myeloma Patients
    Shengyang Peter Wu, Ruth M. Pfeiffer, Inhye E. Ahn, Sham Mailankody, Pieter Sonneveld, Mark van Duin, Nikhil C. Munshi, Brian A. Walker, Gareth John Morgan, Ola Landgren · 2016 · Clinical Cancer Research
  36. Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia
    Marco Benkißer-Petersen, Maike Buchner, Arlette Dörffel, Marcus Duehren-von Minden, Rainer Claus, Kathrin Kläsener, Kerstin Leberecht, Meike Burger, Christine Dierks, Hassan Jumaa et al. · 2016 · PLoS ONE
  37. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells
    Francesco La Rocca, Irma Airoldi, Emma Di Carlo, Pina Marotta, Geppino Falco, Vittorio Simeon, Ilaria Laurenzana, Stefania Trino, Luciana De Luca, Katia Todoerti et al. · 2017 · Cellular Oncology
  38. Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure
    Elizabeth Smyth, Siobhan V. Glavey, Dario Melotti, Patrick Thornton, Jeremy Sargent, Peter J. Conlon, Philip Thomas Murphy, John Quinn · 2018 · Irish Journal of Medical Science (1971 -)
  39. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient
    Irene Ghobrial, Calixto Hernández Cruz, Alfred L. Garfall, Nina D. Shah, Nikhil C. Munshi, Jonathan L. Kaufman, Lawrence Boise, Gareth John Morgan, Viktor A. Adalsteinsson, Salomon Manier et al. · 2019 · Clinical Lymphoma Myeloma & Leukemia
  40. Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations
    Justin R. Arnall, Kathryn T. Maples, Robert Donald Harvey, Donald C. Moore · 2021 · Annals of Pharmacotherapy
  41. The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
    Ivana Lagreca, Giovanni Riva, Vincenzo Nasillo, Patrizia Barozzi, Ilaria Castelli, Sabrina Basso, Francesca Bettelli, Davide Giusti, Angela Cuoghi, Paola Bresciani et al. · 2022 · International Journal of Molecular Sciences
  42. Harnessing immunotherapy for pediatric T-cell malignancies
    Caroline J. Diorio, David T. Teachey · 2020 · Expert Review of Clinical Immunology
  43. Flexibly coupled multiprocessors for image processing
    Myung Hoon Sunwoo, J.K. Aggarwal · 1990 · Journal of Parallel and Distributed Computing
  44. Emissive Synthetic Cofactors: A Highly Responsive NAD + Analogue Reveals Biomolecular Recognition Features
    Jonas Feldmann, Yao Li, Yitzhak Tor · 2019 · Chemistry - A European Journal
  45. Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial‐unfit patients and subsequent therapy
    Sung‐Soo Park, Ja Min Byun, Sung‐Soo Yoon, Kihyun Kım, Sung‐Hoon Jung, Je‐Jung Lee, Chang‐Ki Min · 2020 · British Journal of Haematology
  46. Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China
    Di Shi, Lin Gao, Xiao-Chun Wan, Jin Li, Tian Tian, Jue Hu, Qun-Ling Zhang, Yifan Su, Yu-Peng Zeng, Zi-Juan Hu et al. · 2022 · BMC Medicine
  47. Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study
    Shinsuke Iida, Kenshi Suzuki, Shigeru Kusumoto, Masaki Ri, Nobuhiro Tsukada, Yu Abe, Masayuki Aoki, Mitsuo Inagaki · 2017 · International Journal of Hematology
  48. Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders
    Sanjay De Mel, Joshua Zhi-Chien Tan, Anand Devaprasath D. Jeyasekharan, Wee Joo Chng, Siok‐Bian Ng · 2019 · Frontiers in Pediatrics
  49. The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
    Subhashis Sarkar, Sachin Kumar Singh Chauhan, John M. Daly, Alessandro Natoni, Heather E. Fairfield, Robert B. Henderson, Emma Nolan, Dawn Swan, Jinsong Hu, Michaela Ruth Reagan et al. · 2020 · Cancer Immunology Immunotherapy
  50. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma
    Scott Ryan Goldsmith, Mark Aaron Fiala, Brandon Wang, Mark A. Schroeder, Tanya Marya Wildes, Armin Ghobadi, Keith E Stockerl-Goldstein, Ravi Vij · 2020 · Annals of Hematology
  51. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol
    Issam S. Hamadeh, Emily S. Reese, Justin R. Arnall, Ekaterina Kachur, Allison L. Martin, Meghan Schneider, Reed N. Friend, Barry A. Paul, Shebli Atrash, Manisha Bhutani et al. · 2020 · Clinical Lymphoma Myeloma & Leukemia
  52. Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma
    Wenhao Zhong, Xinyu Zhang, Meng Zhao, Jun Wu, Dongjun Lin · 2020 · Biomaterials Science
  53. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients
    Gill, Sarvarinder K., Unawane, Rashmi, Wang, Shuqi, Ahn, Jaeil, Aleman, Adolfo, Siegel, David S., Vesole, David H., Parmar, Harsh, Phull, Pooja, Biran, Noa · 2022 · Blood Cancer Journal
  54. New monoclonal antibodies on the horizon in multiple myeloma
    Elizabeth O’Donnell, Noopur S Raje · 2016 · Therapeutic Advances in Hematology
  55. AL Amyloidosis: Unfolding a Complex Disease
    Rebecca Lu, Tiffany A. Richards, PhD, ANP-BC · 2019 · Journal of the Advanced Practitioner in Oncology
  56. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
    Kevin Charles Miller, Hamza Hashmi, Sridevi Rajeeve · 2024 · Frontiers in Oncology
  57. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
    Taiga Nishihori, Jinming Song, Kenneth H. Shain · 2016 · Current Hematologic Malignancy Reports
  58. The role of SLAMF7 in multiple myeloma: impact on therapy
    Jean‐Samuel Boudreault, Cyrille Touzeau, Philippe Moreau · 2016 · Expert Review of Clinical Immunology
  59. Multiple myeloma: managing a complex blood cancer
    Maura Dowling, Mary Lou Kelly, Teresa Meenaghan · 2016 · British Journal of Nursing
  60. Current concepts for sensitized patients before transplantation
    Dael R. Geft, JON A. KOBASHIGAWA · 2017 · Current Opinion in Organ Transplantation
  61. A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
    Angela A. Dispenzieri, Anita D’Souza, Morie Abraham Gertz, Kristina M. Laumann, Gregory A. Wiseman, Martha Q. Lacy, Betsy R LaPlant, Francis K. Buadi, Suzanne R. Hayman, Shaji Kunnathu Kumar et al. · 2017 · Bone Marrow Transplantation
  62. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
    Larysa Jessica Sanchez, Joshua Ryan Richter, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, Samir Sunil Parekh, Shambavi Richard, Lowena Tam, Daniel Verina, Ajai Chari · 2021 · Therapeutic Advances in Hematology
  63. Harnessing the Immune System to Fight Multiple Myeloma
    Jakub Krejcik, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, Thomas Stauffer Larsen, Torben Barington, Niels Abildgaard · 2021 · Cancers
  64. Multiple myeloma
    Selina J Chavda, Kwee Yong · 2017 · British Journal of Hospital Medicine
  65. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
    Shih‐Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth Carl Anderson, Yu‐Tzu Tai · 2017 · Antibodies
  66. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison
    Suzy Van Sanden, Tetsuro Ito, Joris Diels, Martin Vogel, Andrew R. Belch, Albert Oriol · 2017 · The Oncologist
  67. Possible targets to treat myeloma-related osteoclastogenesis
    Marina Bolzoni, Denise Toscani, Paola Storti, Valentina Marchica, Federica Costa, Nicola Giuliani · 2018 · Expert Review of Hematology
  68. Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice
    Sung‐Soo Park, Hyeon‐Seok Eom, Jin Seok Kim, Youngil Koh, Chul Won Choi, Je‐Jung Lee, Kihyun Kim, Cheolwon Suh, Jae Hoon Lee, Chang‐Ki Min et al. · 2018 · Japanese Journal of Clinical Oncology
  69. Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation
    Liana Nikolaenko, Saurabh Chhabra, Noa Biran, Arnab Chowdhury, Parameswaran Hari, Amrita Y. Krishnan, Joshua Ryan Richter · 2020 · Clinical Lymphoma Myeloma & Leukemia
  70. Proteomics-inspired precision medicine for treating and understanding multiple myeloma
    Matthew Ho, Giada Bianchi, Kenneth Carl Anderson · 2020 · Expert Review of Precision Medicine and Drug Development
  71. 2,4-Diamino-8-quinazoline carboxamides as novel, potent inhibitors of the NAD hydrolyzing enzyme CD38: Exploration of the 2-position structure-activity relationships
    David N. Deaton, Curt D. Haffner, Brad R. Henke, Michael R. Jeune, Barry G. Shearer, Eugene L. Stewart, J. Darren Stuart, John C. Ulrich · 2018 · Bioorganic & Medicinal Chemistry
  72. Monoclonal Antibodies in the Treatment of Multiple Myeloma
    Niels W.C.J. van de Donk, Sonja Zweegman · 2023 · Hematology/Oncology Clinics of North America
  73. Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab
    Choon Guan Chua, Gin Tsen Chai, Xin Rong Lim, Mona Manghani, Bernard P. L. Leung, Li Wearn Koh · 2023 · Clinical and Experimental Rheumatology
  74. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab
    Matthew Ku, Geoff Chong, Eliza Anne Hawkes · 2016 · Blood Reviews
  75. Seeking Convergence and Cure with New Myeloma Therapies
    Priya Choudhry, Derek C. Galligan, Arun P. Wiita · 2018 · Trends in cancer
  76. A novel dual-cytokine–antibody fusion protein for the treatment of CD38-positive malignancies
    Roberto De Luca, Paul Kachel, Klara Kropivšek, Berend Snijder, Markus Gabriel Manz, Dario Neri · 2018 · Protein Engineering Design and Selection
  77. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti‐CD38 interference in immunohematological testing
    Karen Chinoca Ziza, Tainá A. Paiva, Sabrina Mota, Marcia Regina Dezan, Luciana Cayres Schmidt, Denise Menezes Brunetta, Gustavo Ricci, Fernando Valadares Basques, Fernando Barroso‐Duarte, Vanderson Rocha et al. · 2019 · Transfusion
  78. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
    Dirk Hose, Susanne Beck, Hans Jürgen Salwender, Martina Emde, Uta Bertsch, Christina Kunz, Christof Scheid, Mathias Hänel, Katja Christina Weisel, Thomas Hielscher et al. · 2019 · Journal of Hematology & Oncology
  79. Safety of ninety-minute daratumumab infusion
    Jeffrey Lombardi, Mathieu Boulin, Madeline Devaux, Amélie Cransac, Pauline Pistre, Corinne Pernot, Alexandre Payssot, Ingrid Lafon, Denis Caillot, Pauline Gueneau · 2020 · Journal of Oncology Pharmacy Practice
  80. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience
    Georg Jeryczynski, Marlies Antlanger, Franz Duca, Christina Binder, Thomas Reiter, Ingrid Simonitsch‐Klupp, Diana Bonderman, Renate Kain, Maria‐Theresa Krauth, Hermine Agis · 2021 · ESMO Open
  81. Optimizing transfusion management of multiple myeloma patients receiving daratumumab‐based regimens
    Samantha Phou, Caitlin L. Costello, Patricia M. Kopko, Elizabeth S. Allen · 2021 · Transfusion
  82. Antibody incidence and red blood cell transfusions in patients on daratumumab
    Craig D. Tauscher, Sheila K. Moldenhauer, Sandra C. Bryant, Margaret A. DiGuardo, Eapen K. Jacob · 2021 · Transfusion
  83. Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis
    Kanji Miyazaki, Kenshi Suzuki · 2016 · Amyloid
  84. Which therapies will move to the front line for multiple myeloma?
    María José Cejalvo, Javier de la Rubia · 2017 · Expert Review of Hematology
  85. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients
    Tomáš Jelı́nek, Vladimír Maisnar, Luděk Pour, Ivan Špıčka, Jiří Minařík, Evžen Gregora, Petr Kessler, Michal Sýkora, Hana Fraňková, Dagmar Adamová et al. · 2017 · Current Medical Research and Opinion
  86. HIV protease inhibitors for the treatment of multiple myeloma.
    Max Alberto Mendez-Lopez, Tabea Sutter, Christoph Driessen, Lenka Bešše · 2019 · PubMed
  87. Monoclonal antibodies in multiple myeloma
    Federico Vozella, Francesca Fazio, Gianfranco Lapietra, Maria Teresa Petrucci, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
  88. Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting
    Esther G.M. De Waal, Andor W.J.M. Glaudemans, Carolien P. Schröder, Edo Vellenga, Riemer H. J. A. Slart · 2016 · European Journal of Nuclear Medicine and Molecular Imaging
  89. Immunotherapy and Radiotherapy for Older Cancer Patients during the COVID-19 Era: Proposed Paradigm by the International Geriatric Radiotherapy Group
    Nam Phong Nguyen, Brigitta G. Baumert, Eromosele Oboite, Micaela Motta, Gokula Kumar Appalanaido, Meritxell Arenas, Pedro C. Lara, Marta Bonet, Alice Zamagni, T. Vuong et al. · 2021 · Gerontology
  90. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
    Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik Hellem Schjesvold, Ivan Špıčka, Vladimír Maisnar, Artur J. Jurczyszyn, Zhanet G. Grudeva-Popova, Roman Hájek, Ganna Usenko et al. · 2023 · Haematologica
  91. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
    Shaji Kunnathu Kumar, Brian G.M. Durie, Hareth Nahi, Ravi Vij, Meletios Athanasios Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Xavier P Leleu, Meral Beksaç, Hartmut Goldschmidt et al. · 2018 · Leukemia & lymphoma/Leukemia and lymphoma
  92. Maintenance and continuous therapy for multiple myeloma
    Paul Gerard Guy Richardson, Jacob P. Laubach, Sara Gandolfi, Thierry T.F. Facon, Katja Christina Weisel, Peter O’Gorman · 2018 · Expert Review of Anticancer Therapy
  93. Systemic treatment of a patient with relapsed and refractory extranodal NK/T‐cell lymphoma (ENKL) and meningeosis leukemica with daratumumab
    Stefanie Aeppli, Christoph Driessen, Lukas Graf, Felicitas Hitz · 2018 · Hematological Oncology
  94. Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
    Meral Beksaç, Yıldız Aydın, Hakan Göker, Mehmet Turgut, Sevgi Kalayoğlu Beşışık, Seçkin Çağırgan, Tülin Tuğlular, Filiz Vural, Münci Yağcı, İnci Alacacıoğlu et al. · 2020 · Clinical Lymphoma Myeloma & Leukemia
  95. Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
    Shannon F. Cope, Kabirraaj Toor, Evan Popoff, Rafaël Fonseca, Ola Landgren, María‐Victoria Mateos, Katja Christina Weisel, Jeroen Paul Jansen · 2020 · Value in Health
  96. CD38 targeted treatment for multiple myeloma
    Tomáš Jelı́nek, Jana Mihályová, Roman Hájek · 2018 · Vnitřní lékařství
  97. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
    Trilok Shrivastava, Frits van Rhee, Samer Al Hadidi · 2023 · OncoTargets and Therapy
  98. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database
    Junlin Wu, Han-Biao Wu, Lili Chen, Haiping Liang, Guoning Huang, Sensen Yang, Bishan Chen, Yoshihiro Noguchi, Yonggang Shen · 2023 · Expert Opinion on Drug Safety
  99. Practical Considerations in Managing Relapsed Multiple Myeloma
    Amit Agarwal, Eric Chow, Manisha Bhutani, Peter Michael Voorhees, Reed N. Friend, Saad Z. Usmani · 2016 · Clinical Lymphoma Myeloma & Leukemia
  100. Antibody mimicry, receptors and clinical applications
    Alberto L. Horenstein, Antonella Chillemi, Valeria Quarona, Andrea Zito, Valentina Mariani, Angelo Corso Faini, Fabio Morandi, Ilaria Schiavoni, Clara Maria Ausiello, Fabio Malavasi · 2016 · Human Antibodies